Neoadjuvant Pembrolizumab in Cutaneous Squamous Cell Carcinoma

This trial studies whether giving the immunotherapy drug pembrolizumab (Keytruda) before surgery can shrink locally advanced skin squamous cell carcinoma tumors and improve outcomes. Patients receive a few doses before their surgery, and researchers look at how the tumor responds. **You may be eligible if...** - You have been diagnosed with invasive, locally advanced skin squamous cell carcinoma (Stage II–IV) - Your medical team has already determined surgery and post-surgery radiation are needed - You have measurable disease and are in good general health (ECOG 0–1) - You have adequate organ function and a tumor tissue sample available **You may NOT be eligible if...** - Your cancer has recurred in the same spot after 2 or more surgeries - Your tumor originates from nasal mucosa or glabrous (non-hair-bearing) skin without specialist approval - You have had prior immunotherapy that caused severe side effects - Your organ function does not meet study requirements Talk to your doctor to see if this trial is right for you.